Webinar
The Future of Small Molecules-Why Chemistry Is Far From Dead
Submit the form to access the webinar
Register Now
More About the Webinar
Chemistry has been declared “obsolete” more times than we can count. Yet, small molecules continue to shape the future of medicine, materials, and innovation, forming the backbone of global therapeutics. This webinar challenges the narrative of decline and reveals why chemistry is thriving at the cutting edge of science and holds strategic relevance in a market increasingly shaped by biologics, gene therapy, and cell therapy. From affordability, oral delivery, and manufacturing scalability to the rise of modern chemistry, molecular engineering, structure-based design, and AI-driven discovery, the discussion will highlight the evolution of small molecules. Bringing together strategic, scientific, and commercial perspectives, this webinar is designed for biopharma innovation leaders, R&D experts, and business development specialists, looking to understand where small molecules stand today and where the next wave of opportunity will come from.
Webinar Agenda
- While biologics dominate headlines, chemistry is being reinvented: Despite biologics’ scientific prestige, small molecules still account for nearly 2/3rd of FDA approvals in the past decade.
- Small molecules are not just scientifically relevant but economically indispensable: ~45% of Medtech companies wish to diversify supply chains regionally, because next disruptions may not resemble the COVID-19 pandemic, but would be hidden or second-order risks that this webinar will focus on.
- Traditional drug design is being reimagined with modern tools: Investment is flowing back into chemistry with drug discovery market rising to $103.1B in 2031, by merging centuries- old chemistry with machine learning, wherein design is faster, smarter, and more precise.
- Transformative Innovation Trends: AI-driven design has accelerated small molecule discovery pipelines by up to 70%, cutting years of development timelines.
- Faster approvals shift investor preference: Small molecules reach approval 0–2 years faster than biologics, driving speed advantage influenced competitive strategy in pharma.
- Small molecules still remain the economic engine: 70–85% of global pharma revenue comes from small molecules, while affecting R&D priorities and role in equitable healthcare access in the next decade
Meet the Speakers
Tanu Kapoor is Assistant Manager – Life Sciences at Stellarix, with nearly a decade of experience at the nexus of strategic consulting, intellectual property intelligence, and biopharma innovation. She leads initiatives that empower global healthcare organizations to unlock value from cutting-edge research and emerging technologies. Her expertise spans technology assessment, competitive intelligence, and future-focused strategy development, enabling industry leaders to strengthen R&D pipelines, navigate complex IP landscapes, and accelerate translational insights into market-ready solutions. With experience collaborating with multinational organizations, she brings sharp analytical acumen to identify opportunities, mitigate risks, and drive sustainable growth in an evolving healthcare ecosystem. Passionate about innovation, she is dedicated to shaping strategies that bridge science, business, and intellectual property for long-term impact.
Damini Goyal is Project Leader – Life Sciences at Stellarix, with over six years of experience in strategic consulting and healthcare intelligence, Damini partners with biopharma leaders to transform complex scientific and market landscapes into clear, actionable strategies. She specializes in mapping innovation ecosystems, tracking competitive activity, and evaluating emerging technologies to guide high-stakes decision-making. She has successfully led diverse engagements spanning early-stage innovation assessments, market access evaluations, and IP-driven strategic insights across multiple therapeutic areas. By combining structured problem-solving with deep domain understanding, she identifies high-impact opportunities, uncovers whitespace potential, and supports end-to-end decision-making for global organizations. Her approach centers on delivering concise, client-ready insights that bridge science, strategy, and business outcomes—whether shaping R&D priorities, guiding partnerships, or enabling sustainable growth in a rapidly evolving healthcare ecosystem.